156 related articles for article (PubMed ID: 35568330)
41. Proportion of Severe Asthma Patients Eligible for Mepolizumab Therapy by Age and Age of Onset of Asthma.
Comberiati P; McCormack K; Malka-Rais J; Spahn JD
J Allergy Clin Immunol Pract; 2019; 7(8):2689-2696.e2. PubMed ID: 31201938
[TBL] [Abstract][Full Text] [Related]
42. Rapid and Consistent Improvements in Morning PEF in Patients with Severe Eosinophilic Asthma Treated with Mepolizumab.
Ortega H; Menzies-Gow A; Llanos JP; Forshag M; Albers F; Gunsoy N; Bradford ES; Yancey SW; Kraft M
Adv Ther; 2018 Jul; 35(7):1059-1068. PubMed ID: 29949045
[TBL] [Abstract][Full Text] [Related]
43. Treatment of a case of pediatric hypereosinophilic syndrome with anti-interleukin-5.
Mehr S; Rego S; Kakakios A; Kilham H; Kemp A
J Pediatr; 2009 Aug; 155(2):289-91. PubMed ID: 19619754
[TBL] [Abstract][Full Text] [Related]
44. [Use of mepolizumab in hypereosinophilic syndromes: The position and proposals of the national reference center for hypereosinophilic syndromes].
Kahn JE; Lefèvre G; Groh M
Rev Med Interne; 2023 Apr; 44(4):155-157. PubMed ID: 36997273
[No Abstract] [Full Text] [Related]
45. Mepolizumab in eosinophilic disorders.
Abonia JP; Putnam PE
Expert Rev Clin Immunol; 2011 Jul; 7(4):411-7. PubMed ID: 21790283
[TBL] [Abstract][Full Text] [Related]
46. Safety and efficacy of the monoclonal anti-interleukin-5 antibody SCH55700 in the treatment of patients with hypereosinophilic syndrome.
Klion AD; Law MA; Noel P; Kim YJ; Haverty TP; Nutman TB
Blood; 2004 Apr; 103(8):2939-41. PubMed ID: 15070668
[TBL] [Abstract][Full Text] [Related]
47. Preclinical efficacy and safety of mepolizumab (SB-240563), a humanized monoclonal antibody to IL-5, in cynomolgus monkeys.
Hart TK; Cook RM; Zia-Amirhosseini P; Minthorn E; Sellers TS; Maleeff BE; Eustis S; Schwartz LW; Tsui P; Appelbaum ER; Martin EC; Bugelski PJ; Herzyk DJ
J Allergy Clin Immunol; 2001 Aug; 108(2):250-7. PubMed ID: 11496242
[TBL] [Abstract][Full Text] [Related]
48. Mepolizumab decreases tissue eosinophils while increasing type-2 cytokines in eosinophilic chronic rhinosinusitis.
Walter S; Ho J; Alvarado R; Smith G; Croucher DR; Liang S; Grayson JW; Mangussi-Gomes J; Van Es SL; Earls P; Rimmer J; Campbell R; Kalish L; Sacks R; Harvey RJ
Clin Exp Allergy; 2022 Dec; 52(12):1403-1413. PubMed ID: 35475305
[TBL] [Abstract][Full Text] [Related]
49. Characterization of the relationship between dose and blood eosinophil response following subcutaneous administration of mepolizumab.
Pouliquen IJ; Kornmann O; Barton SV; Price JA; Ortega HG
Int J Clin Pharmacol Ther; 2015 Dec; 53(12):1015-27. PubMed ID: 26445140
[TBL] [Abstract][Full Text] [Related]
50. Assessment of the long-term safety of mepolizumab and durability of clinical response in patients with severe eosinophilic asthma.
Khatri S; Moore W; Gibson PG; Leigh R; Bourdin A; Maspero J; Barros M; Buhl R; Howarth P; Albers FC; Bradford ES; Gilson M; Price RG; Yancey SW; Ortega H
J Allergy Clin Immunol; 2019 May; 143(5):1742-1751.e7. PubMed ID: 30359681
[TBL] [Abstract][Full Text] [Related]
51. Idiopathic hypereosinophilic syndrome in remission with benralizumab treatment after relapse with mepolizumab.
Fujii K; Takahashi H; Hayakawa N; Iwasaki Y
Respirol Case Rep; 2020 Nov; 8(8):e00665. PubMed ID: 33005423
[TBL] [Abstract][Full Text] [Related]
52. Severe hypereosinophilic syndrome successfully treated with a monoclonal antibody against interleukin 5 receptor α - benralizumab.
Kosałka-Węgiel J; Milewski M; Siwiec A; Strach M; Ochrem B; Korkosz M
Cent Eur J Immunol; 2021; 46(3):395-397. PubMed ID: 34764813
[TBL] [Abstract][Full Text] [Related]
53. Case report: Successful use of mepolizumab for immune checkpoint inhibitors-induced hypereosinophilic syndrome in two patients with solid malignancies.
Lazzari C; Yacoub MR; Campochiaro C; Bulotta A; Palumbo D; Ogliari FR; Dagna L; Marchesi S; Ponzoni M; Gregorc V
Front Oncol; 2023; 13():1079034. PubMed ID: 36776300
[TBL] [Abstract][Full Text] [Related]
54. Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial.
Chupp GL; Bradford ES; Albers FC; Bratton DJ; Wang-Jairaj J; Nelsen LM; Trevor JL; Magnan A; Ten Brinke A
Lancet Respir Med; 2017 May; 5(5):390-400. PubMed ID: 28395936
[TBL] [Abstract][Full Text] [Related]
55. Ability of Serum IgE Concentration to Predict Exacerbation Risk and Benralizumab Efficacy for Patients with Severe Eosinophilic Asthma.
Jackson DJ; Humbert M; Hirsch I; Newbold P; Garcia Gil E
Adv Ther; 2020 Feb; 37(2):718-729. PubMed ID: 31836949
[TBL] [Abstract][Full Text] [Related]
56. Benralizumab for
Kuang FL; Legrand F; Makiya M; Ware J; Wetzler L; Brown T; Magee T; Piligian B; Yoon P; Ellis JH; Sun X; Panch SR; Powers A; Alao H; Kumar S; Quezado M; Yan L; Lee N; Kolbeck R; Newbold P; Goldman M; Fay MP; Khoury P; Maric I; Klion AD
N Engl J Med; 2019 Apr; 380(14):1336-1346. PubMed ID: 30943337
[TBL] [Abstract][Full Text] [Related]
57. Justification of the Subcutaneous Mepolizumab Dose of 300 mg in Eosinophilic Granulomatosis With Polyangiitis and Hypereosinophilic Syndrome.
Pouliquen IJ; Austin D; Steinfeld J; Yancey SW
Clin Ther; 2021 Jul; 43(7):1278-1280. PubMed ID: 34187697
[No Abstract] [Full Text] [Related]
58. Reduced need for surgery in severe nasal polyposis with mepolizumab: Randomized trial.
Bachert C; Sousa AR; Lund VJ; Scadding GK; Gevaert P; Nasser S; Durham SR; Cornet ME; Kariyawasam HH; Gilbert J; Austin D; Maxwell AC; Marshall RP; Fokkens WJ
J Allergy Clin Immunol; 2017 Oct; 140(4):1024-1031.e14. PubMed ID: 28687232
[TBL] [Abstract][Full Text] [Related]
59. Rebound eosinophilia after treatment of hypereosinophilic syndrome and eosinophilic gastroenteritis with monoclonal anti-IL-5 antibody SCH55700.
Kim YJ; Prussin C; Martin B; Law MA; Haverty TP; Nutman TB; Klion AD
J Allergy Clin Immunol; 2004 Dec; 114(6):1449-55. PubMed ID: 15577851
[TBL] [Abstract][Full Text] [Related]
60. Impact of baseline clinical asthma characteristics on the response to mepolizumab: a post hoc meta-analysis of two Phase III trials.
Lemiere C; Taillé C; Lee JK; Smith SG; Mallett S; Albers FC; Bradford ES; Yancey SW; Liu MC
Respir Res; 2021 Jun; 22(1):184. PubMed ID: 34158028
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]